Increasing evidence shows an elevated risk of venous thromboembolism (VTE) in antipsychotic drug users. |
In general, no well-documented differences in the occurrence rate of VTE between first- and second-generation antipsychotics or between individual antipsychotic drugs have been shown. |
The biological mechanisms involved in the pathogenesis of antipsychotic-induced VTE are still largely unknown. |
Physicians should be aware of this potentially serious adverse drug reaction and consider discontinuing or switching the antipsychotic treatment in patients experiencing VTE. |
The threshold for considering prophylactic antithrombotic treatment should be low when risk situations for VTE arise in users of antipsychotics. |
1 Introduction
Clinical factors | Surgical factors | Inherited factors |
---|---|---|
Advanced age Hospitalisation for acute medical illness Long-haul flights (duration > 4 h) Obesity Pregnancy, including the post-partum period | Central venous access Major surgery Orthopaedic surgery Trauma or fracture | Antithrombin deficiency Dysfibrinogenemia Factor V Leiden mutation Protein C deficiency Protein S deficiency Prothrombin 20210A mutation |
Medical diseases | Drugs | Mixed or unknown factors |
---|---|---|
Antiphospholipid syndrome Congestive heart failure Inflammatory bowel disease Malignancy Myeloproliferative disorders Myocardial infarction Polycythemia vera Previous VTE Sepsis Stroke Varicose veins | Antiestrogens Antipsychotics Chemotherapy Heparin-induced thrombocytopenia High-dose therapy with progestogens Hormone replacement therapy Oral contraceptives Vaginal ring for contraception Strontium ranelate Thalidomide and lenalidomide | Activated protein C resistance in the absence of factor V Leiden mutation Family history of VTE High levels of factor VIII Hyperhomocysteinaemia Lupus anticoagulant |
2 Early Studies
Study, year | Study design | Data source | Time period | Total population | Study population | Age (years) | Case definition | Previous VTE excluded | Results (95% CI) |
---|---|---|---|---|---|---|---|---|---|
General patient populations
| |||||||||
Zornberg and Jick, 2000 [13] | Nested case–control study | The GPRD, UKa | 1990–1998 | 29,952 users of AP in the UK | 42 cases of VTE and 172 controls | < 60 | Patients with a first-ever recorded VTE | Yes | aOR, FGA: 7.1 (2.3–22.0) LP FGA: 24.1 (3.3–172.7) HP FGA: 3.3 (0.8–13.2) |
Lacut et al., 2007 [33] | Case–control study | Hospital-based, case records, interviews, France | 2000–2004 | All patients hospitalised due to VTE | 677 cases and 677 controls | ≥ 18 | All patients hospitalised due to VTE | Yes for controls, no for cases | OR, AP: 3.5 (2.0–6.2) FGA: 4.1 (2.1–8.2) SGA: 2.7 (0.7–10.0) |
Masopust et al., 2007 [34] | Case–control study | Electronic case records, one university hospital, Czech Republic | 1996–2004 | All patients hospitalised at an internal medicine department | 266 cases and 274 controls with hypertension | 18–60 | Patients hospitalised due to VTE or hypertension (controls) | Not stated | OR, AP: 2.8 (1.0–7.6) |
Jönsson et al., 2009 [35] | Population-based case–control study | Hospital discharge registries and prescription database, Denmark | 1997–2005 | All 1.1 million inhabitants in two counties | 5999 cases (3823 DVT, 2176 PE) and 59,990 matched controls | All ages | Patients with a first-time diagnosis of VTE | Yes | aOR, AP: 2.0 (1.7–2.3) LP FGA: 2.1 (1.5–3.0) HP FGA: 1.8 (1.5–2.3) SGA: 2.5 (1.9–3.3) |
Parker et al., 2010 [36] | Population-based nested-case control study | The QResearch primary care database, UK | 1996–2007 | All 7.27 million patients registered by 453 UK GPs | 25,532 cases (15,975 DVT, 9557 PE) and 89,491 matched controls Chlorpromazine: 113 cases Haloperidol: 149 cases Olanzapine: 102 cases Prochlorperazine: 1525 cases Quetiapine: 58 cases Risperidone: 148 cases Trifluoperazine: 82 cases | 16–100 | Patients with a first ever recorded VTE | Yes | aOR, any AP use: 1.3 (1.2–1.4) Current AP use: 1.6 (1.4–1.8) New AP use: 2.0 (1.7–2.3) FGA: 1.3 (1.2–1.4) LP FGA 2.0 (1.5–2.6) HP FGA 1.7 (1.4–2.2) SGA: 1.7 (1.4–2.2) Chlorpromazine: 1.8 (1.3–2.5) Haloperidol: 2.2 (1.6–3.0) Olanzapine: 1.5 (1.1–2.1) Prochlorperazine: 1.2 (1.1–1.3) Quetiapine: 2.8 (1.8–4.5) Risperidone: 1.2 (0.9–1.7) Trifluoperazine: 1.3 (0.9–1.9) |
Ishiguro et al., 2014 [37] | Nested case–control study | The CPRD, UK | 1998–2012 | 810,000 patients with at least one filled prescription for any AP during the study period | 868 cases of VTE, 3158 matched controls Chlorpromazine: 5 cases Haloperidol: 5 cases Olanzapine: 16 cases Prochlorperazine: 42 cases Risperidone: 12 cases | 20–59 | Diagnosis of incident VTE | Yes | aOR: Current AP users: 1.3 (1.0–1.6) New AP users: 3.2 (1.6–6.3) FGA: 1.3 (0.9–1.8) LP FGA: 0.7 (0.3–1.5) HP FGA: 1.5 (1.0–2.1) SGA: 1.2 (0.8–1.9) Chlorpromazine: 1.0 (0.4–2.8) Haloperidol: 1.2 (0.4–3.5) Olanzapine: 1.3 (0.7–2.5) Prochlorperazine: 2.2 (1.5–3.2) Risperidone: 1.8 (0.9–3.8) |
Wu et al., 2013 [38] | Case–control study | National health insurance research database, Taiwan | 2001–2010 | 1,000,000 individuals | 2162 cases of VTE 12,966 matched controls | ≥ 16 | Hospitalisation for VTE or an outpatient VTE with intravenous or subcutaneous anticoagulant therapy | Yes (cases with a VTE in the year 2000 were excluded) | aORs: Current users of AP: 1.5 (1.2–1.9) New users of AP: 3.3 (2.1–5.2) Continuous users of AP: 1.2 (0.9–1.6) New users of LP FGA: 2.9 (1.6–5.2) New users of HP FGA: 3.4 (1.1–10.3) New users of SGA: 4.0 (1.2–12.9) Continuous users: NS differences for either FGA or SGA |
Wang et al., 2016 [39] | Case–control study | National health insurance research database, Taiwan | 2000–2011 | 316,000 women | 2520 cases and 24,223 matched controls Amisulpride: 6 cases Aripiprazole: 6 cases Clothiapine: 3 cases Droperidol: 5 cases Flupentixol: 53 cases Haloperidol: 48 cases Olanzapine: 10 cases Prochlorperazine: 115 cases Quetiapine: 66 cases Risperidone: 45 cases Sulpiride: 70 cases Thioridazine: 3 cases Trifluoperazine: 5 cases | ≥ 50 | Diagnosis of VTE treated with anticoagulants or thrombectomy | Yes | aORs Current users of AP: 1.9 (1.6–2.2) New users of AP: 2.1 (1.5–2.8) Continuous users of AP: 1.9 (1.6–2.2) FGA: 1.8 (1.5–2.1) SGA: 1.9 (1.4–2.7) Amisulpride: 5.4 (2.0–14.6) Aripiprazole: 9.4 (2.8–31.8). Clothiapine: 4.7 (0.9–24.4) Droperidol: 3.8 (1.1–12.3) Flupentixol: 1.1 (0.8–1.5) Haloperidol: 2.6 (1.8–3.8) Olanzapine: 4.7 (2.2–10.1) Prochlorperazine: 2.7 (2.1–3.4) Quetiapine: 1.9 (1.4–2.5) Risperidone: 2.7 (1.8–3.9) Sulpiride: 1.5 (1.1–2.0) Thioridazine: 1.3 (0.4–4.8) Trifluoperazine: 3.8 (1.3–11.3) |
Conti et al., 2015 [40] | Case–control study | Healthcare system in Lombardy, Italy | 2012–2013 | 144,000 AP users | 232 cases of PE, 4353 matched controls | ≥ 18 | Diagnosis of PE | No? | aOR current compared with past use AP 2.3 (1.2–4.6). FGA 3.5 (1.7–7.4) SGA 2.0 (1.0–4.0) |
Premuš Marušič et al., 2017 [41] | Case–control study | Medical records of the Murska Sobota General Hospital, Slovenia | 2007–2011 | 286 patients treated at the surgical department | 144 cases and 142 controls. 21 cases and 15 controls used AP | All | Diagnosis of DVT or PE within 180 days after surgical treatment | Yes | Univariate analysis p = 0.3, not included in the regression analyses |
Elderly patient populations
| |||||||||
Kleijer et al., 2010 [42] | Time-matched, nested, case–control study | The PHARMO Institute’s record linkage system, The Netherlands | 1998–2008 | 112,000 new users of AP | 1032 cases (367 DVT, 342 PE and 323 outpatients) and 4125 controls | ≥ 60 | VTE diagnosis or start of treatment with LMWH in combination with vitamin K antagonists | No? | aOR, SGA: 0.9 (0.7–1.1) vs. FGA |
Schmedt and Garbe, 2013 [43] | Case–control study | The German pharmacoepidemiological research database (GePaRD), Germany | 2004–2007 | 73,000 patients with dementia | 1028 cases and 4109 controls | ≥ 65 | Hospitalisations due to VTE | No | aOR, AP: 1.2 (1.0–1.5) FGA: 0.89 (0.6–1.2) SGA: 0.94 (0.7–1.2) FGA and SGA: 1.6 (1.2–2.3) |
Deceased patient populations
| |||||||||
Walker et al., 1997 [11] | Case–control study | The US national registry of clozapine recipients and National death register, USA | 1991–1993 | 67,000 current and former clozapine users | 396 deaths in 85,399 person-years; 19 deaths due to PE, 18 used AP | 10–54 | Fatal PE | Not stated | RR for current clozapine use compared with previous use = 5.2 |
Parkin et al., 2003 [44] | Case–control study | Coroner’s records (cases) and GP records (cases and controls), New Zealand | 1990–1998 | All residents in New Zealand aged 15–59 years | 62 cases and 243 GP-based controls | 15–59 | Persons deceased due to VTE | Yes | aOR AP: 13.3 (2.3–76.3) LP FGA: 20.8 (1.7–259.0) |
Hamanaka et al., 2004 [45] | Retrospective prevalence study with a control group | Medico-legal autopsy records, Japan | 1998–2002 | 1125 forensic autopsies | 34 individuals using AP and 28 with PE | All ages | PE diagnosed at autopsy | NA | aOR AP: 10.5 (4.0–27.9) |
Study, year | Study design | Data source | Time period | Total population | Study population | Age (years) | Case definition | Previous VTE excluded | Results (95% CI) |
---|---|---|---|---|---|---|---|---|---|
General patient populations
| |||||||||
Allenet et al., 2012 [46] | Cohort study | The Premier’s Perspective’ database, USA | 2006 | Among 29,000,000 adults, including 450,951 patients with at least one AP prescription (46% had psychotic disorders) Aripiprazole: 31,130 users Chlorpromazine: 19,330 users Clozapine: 5366 users Haloperidol: 157,667 users Olanzapine: 69,975 users Risperidone: 99,890 users Quetiapine: 142,964 users Ziprasidone: 40,980 users | 76,814 cases of PE | ≥ 18 | Hospitalisations due to PE | No | aOR, AP: 1.2 (1.1–1.2) FGA 1.2 (1.1–1.3) SGA 1.2 (1.1–1.2) Aripiprazole: 0.98 (0.83–1.15) Chlorpromazine: 1.19 (1.03–1.38) Clozapine: 1.46 (1.05–2.02) Haloperidol: 1.17 (1.11–1.24) Olanzapine: 1.12 (1.03–1.22) Risperidone: 1.15 (1.07–1.23) Quetiapine: 0.97 (0.91–1.04) Ziprasidone: 1.21 (1.07–1.38) |
Hsu et al., 2015 [47] | Cohort study | National health insurance research database, Taiwan | 1996–2011 | 60,000 patients with schizophrenia and 60,000 control patients without schizophrenia | 161 cases of DVT and 55 cases of PE among patients with schizophrenia 79 cases of DVT and 27 cases of PE among control patients | > 20 | Diagnoses of VTE | Yes | aHR, FGA users vs. non-schizoprenia patients: for DVT 2.09 (1.55–2.81); for PE 1.93 (1.16–3.22) aHR, SGA users vs. non-schizoprenia patients: for DVT 1.74 (1.05–2.90); for PE 2.42 (1.12–5.24) |
Ferraris et al., 2017 [48] | Retrospective cohort study | Electronic database of a tertiary teaching hospital in Buenos Aires, Argentina | 2002–2007 | 1008 new users of AP (66% had dementia, 12 % bipolar disorder, 9% schizophrenia) | 184 cases of VTE | 30–90 | Time to first VTE | Yes | aHR, AP with high risk for sedation/metabolic abnormalities vs. low risk 1.23 (0.74–2.04) aHR, AP with high risk for hyperprolactinaemia and thromboembolism events vs. low risk 0.81 (0.50–1.35) |
Hippisley-Cox and Coupland, 2011 [49] | Cohort study | The QResearch database England and Wales | 2004–2010 | 2,315,000 patients | 14,756 cases of VTE | 25–84 | VTE diagnosis | Yes | aHR, AP in women 1.55 (1.32–1.81); AP in men 1.84 (1.51–2.23) |
Nakamura et al., 2017 [50] | Cohort study | The EBM provider healthcare database, Japan | 2008–2013 | 3554 patients diagnosed with VTE in 100 acute care hospitals (10% of all acute care admissions in Japan) | 26 cases of VTE in 350 users of AP vs. 199 cases of VTE in 3204 non-users of AP | All ages | Recurrent VTE diagnosis | No | aHR 1.6 (1.0–2.4) |
Elderly patient populations
| |||||||||
Ray et al., 2002 [51] | Retrospective cohort study | Healthcare administrative databases: Ontario Drug Benefits database, Canadian Institute for Health Information Discharge Abstract Database, OHIP database, Canada | 1994–2000 | Individuals with prescriptions of AP (n = 23,000), AD (n = 76,000) or TH (n = 33,000) within the OHIP database Haloperidol: 8508 users | Cases of VTE per 1000 person-years of users: 19.2 for AP, 12.0 for TH and 14.3 for AD | ≥ 65 | Diagnosis of DVT or PE | Yes | aHR, AP: 1.1 (0.95–1.3) vs. TH treatment Haloperidol: 1.4 (1.2–1.7) |
Liperoti et al., 2005 [52] | Retrospective cohort study | The minimum dataset, Medicare inpatient claims, USA | 1998–1999 | 19,940 new users of APs (73% had dementia, 45% depression, 20% anxiety) and 112,078 non-users in nursing home residents in five states Clozapine/quetiapine: 977 users Risperidone: 7811 users Olanzapine: 2825 users | 28 cases of VTE among FGA AP users 64 cases of VTE in users of SGAs | ≥ 65 | Hospitalisations due to VTE | No | aHR FGAs 1.0 (0.7–1.6) SGAs 2.0 (1.5–2.7) Clozapine/quetiapine 2.7 (1.2–6.3) Risperidone 2.0 (1.4–2.8) Olanzapine 1.9 (1.1–3.3) |
Dennis et al., 2017 [53] | Cohort study | The Welsh Secure Anonymised Information Linkage databank | 2003–2011 | 9674 patients newly diagnosed with dementia | 37,535 exposed to AP | ≥ 65 | VTE | No | PERR: AP 1.95 (1.83–2.0) |
Deceased patient populations
| |||||||||
Jönsson et al., 2008 [54] | Medico-legal autopsy series | Swedish medico-legal autopsy register | 1992–2005 | 14,439 medico-legal autopsy cases | PE was recorded as the cause of death in 279 participants, 33 of whom used AP | 18–65 | Fatal PE determined by a forensic pathologist | Yes | aOR LP FGA: 2.39 (1.46–3.92) SGA 6.91 (3.95–12.10) |
Adverse drug reaction surveillance programmes
| |||||||||
Hägg et al., 2000 [12] | Case series | The Swedish ADR database | 1989–2000 | All ADR case records 1989–2000 | 12 cases of VTE during treatment with clozapine (8 patients had schizophrenia, 4 psychosis), 3 cases of VTE during treatment with all other APs | 18–60 | Reported VTE | A conservative risk estimate was 1 case per 2000–6000 clozapine-treated patients | |
Hägg et al. 2008 [55] | Data mining | The WHO ADR database, worldwide | 1975–2004 | 3.2 million ADR case records | 734 cases of VTE during APs treatment | All ages | Reported VTE | Significantly more VTE events than expected reported for clozapine (n = 385), olanzapine (n = 99). sertindole (n = 6) and zuclopenthixol (n = 10) | |
Letmaier et al., 2017 [56] | Cohort study | Multicentre drug surveillance programme for psychiatric inpatients: Germany, Austria and Switzerland | 1993–2011 | 264,422 treated patients with AP (49 % had schizophrenia, 25% mood disorders, 26% other) in 99 psychiatric hospitals Amisulpride: 10,665 users Aripirazole: 8421 users Chlorprothixene: 12,282 users Clozapine: 33,213 users Flupentixol: 3032 users Fluphenazine: 3032 users Haloperidol: 36,156 users Levomepromazine: 11,851 users Melperone: 16,769 users Olanzapine: 41,903 users Perazine: 15,168 users Pipamperone: 18,102 users Promethazine: 14,006 users Prothipendyl: 10,778 users Quetiapine: 42,171 users Risperidone: 39,749 users Zuclopenthixol: 9486 users | 89 inpatients with VTE | All ages | Diagnosis of VTE | No | Overall 3.4 cases per 10,000 inpatient admissions Amisulpride: 3.8 cases per 10,000 Aripiprazole: 0 cases per 10,000 Chlorprothixene: 1.6 cases per 10,000 Clozapine: 4.8 cases per 10,000 Fluphenazine: 0 cases per 10,000 Flupentixol: 1.5 cases per 10,000 Haloperidol: 5.3 cases per 10,000 Levomepromazine: 4.2 cases per 10,000 Melperone: 3.0 cases per 10,000 Olanzapine: 2.9 cases per 10,000 Perazine: 2.0 cases per 10,000 Pipamperone: 6.1 cases per 10,000 Promethazine: 3.6 cases per 10,000 Prothipendyl: 4.6 cases per 10,000 Quetiapine: 1.7 cases per 10,000 Risperidone: 5.5 cases per 10,000 Zuclopenthixol: 4.2 cases per 10,000 |
3 Case–Control Studies
3.1 General Patient Populations
3.2 Elderly Patient Populations
3.3 Deceased Patient Populations
4 Cohort Studies
4.1 General Patient Populations
4.2 Elderly Patient Populations
4.3 Deceased Patient Populations
4.4 Adverse Drug Reaction Surveillance Programmes
5 Meta-Analyses
6 Interpretation of Observational Studies
7 Biological Mechanism
8 Clinical Implications and Management
Score 2 risk factors | Score 1 risk factors |
---|---|
History of deep vein thrombosis or pulmonary embolism Malignancy (active/treated) Age ≥ 75 years Acute infection (including severe infection/sepsis) or acute respiratory disease (including exacerbation of chronic respiratory disease) | Immobilisation (including paralysis of lower extremity, physical restraint ≥ 8 h, catatonia) Hormone therapy (oral contraceptiona, hormonal replacement therapy) Obesity (body mass index ≥ 30 kg/m2) Age 60–74 years Varicose veins/venous insufficiency Dehydrationa Thrombophilia (laboratory)a Treatment with antipsychotics |
Patients with risk factors for VTE besides the antipsychotic treatment should be informed of VTE as a possible adverse effect, early symptoms of VTE, and the importance of seeking medical care immediately if a VTE is suspected |
Early symptoms of VTE should be recognised and further investigated without delay by healthcare providers |
Prevention of VTE with low-molecular weight heparin is generally considered safe and effective and should be considered in antipsychotic users restrained for more than 24 h due to psychotic uncontrollable behaviour |
The threshold for initiating prophylactic treatment with low-molecular weight heparins should be low in other VTE high-risk situations (for example, fractures, surgery and reduced mobility) |
A manifest VTE should be treated according to current VTE management guidelines |
After a diagnosis of VTE has been made in an antipsychotic drug user, the indication of the antipsychotic treatment should be re-evaluated and treatment suspended whenever possible, or, alternatively, switched to another antipsychotic compound |